Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 10/20 | 0.45 |
| ▸ | DRD2 | P14416 | 8/20 | 0.44 |
| ▸ | HTR6 | P50406 | 8/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.42 |
| ▸ | HTR7 | P34969 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2782104 | 0.90 | KDM4E (0.45) | HTR1ADRD2HTR6SLC6A4HTR7 | |
| SCHEMBL3766147 | 0.82 | PPARG (0.52) | HTR1ADRD2HTR6PPARGPPARA | |
| SCHEMBL2781815 | 0.76 | KDM4E (0.45) | HTR1ADRD2HTR6SLC6A4HTR7 | |
| SCHEMBL4827565 | 0.73 | DRD2 (0.53) | HTR1ADRD2HTR6SIGMAR1 | |
| SCHEMBL3772285 | 0.72 | CCNT1 (0.44) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL2781703 | 0.71 | DRD2 (0.75) | HTR1ADRD2HTR6HTR7SIGMAR1 | |
| SCHEMBL27887860 | 0.70 | KDM4E (0.44) | HTR1ADRD2HTR6SLC6A4HTR7 | |
| SCHEMBL18396148 | 0.70 | DRD2 (0.49) | HTR1ADRD2HTR6SIGMAR1 | |
| SCHEMBL2928327 | 0.70 | SIGMAR1 (0.51) | HTR6HTR7PPARGPPARASIGMAR1 | |
| SCHEMBL2782275 | 0.69 | DRD2 (0.55) | DRD2HTR6SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | disclosed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | disclosed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
| EP-1773772-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005121087-A1 | NEW DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | HTR1A 26/4885DRD2 1/4885HTR6 95/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | HTR1A 27/4885DRD2 1/4885HTR6 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.